ArticleBMC infectious diseases2026
Optimising pulmonary tuberculosis diagnosis in adults: diagnostic usefulness of stool gene xpert alone and in combination with sputum gene xpert at a referral centre in Northeastern Nigeria.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePulmonary tuberculosis (PTB) continues to be a major public health burden, a situation exacerbated by significant diagnostic gaps. Conventional testing relies heavily on sputum samples, but many patients are unable to produce adequate and qualitative sputum. This limitation leaves a number of cases undiagnosed. Microbiological diagnosis of pulmonary tuberculosis relies mainly on smear microscopy and Xpert MTB/RIF on sputum samples, but obtaining good-quality sputum samples may be difficult. Stool GeneXpert, a molecular diagnostic test, has shown potential as an alternative specimen for diagnosing PTB. This study aimed to evaluate the diagnostic performance of stool GeneXpert, both as a standalone test and in combination with sputum GeneXpert, for diagnosing PTB in adults in Northeastern Nigeria.
methodsThis retrospective descriptive study was conducted at the Federal Teaching Hospital, Gombe, in Northeastern Nigeria, and included data collected between January 2023 and October 2024. Adult patients suspected of having PTB and tested with sputum and/or stool GeneXpert were included. Data were collected from medical records, including demographic details, HIV status, diagnostic test results, and patient weight. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated for stool GeneXpert and the combination of stool and sputum GeneXpert. McNemar test, Receiver Operating Characteristic (ROC) curve analysis, and logistic regression were used to evaluate diagnostic performance and identify factors influencing diagnostic outcomes.
resultsA total of 318 patients were included. The diagnostic yield of stool GeneXpert alone was 72.1%, higher than sputum GeneXpert at 64.3%. The combined stool and sputum GeneXpert testing achieved a diagnostic yield of 83.7%, with 100% sensitivity and 100% NPV. The McNemar test showed no significant difference between stool and sputum GeneXpert results (p = 0.164). However, combining both samples significantly improved detection (p = 0.000). ROC analysis demonstrated a modest discriminatory ability for stool GeneXpert (AUC = 0.621), which improved moderately when combined with sputum GeneXpert (AUC = 0.728).
conclusionStool GeneXpert, particularly when combined with sputum GeneXpert, offers a promising alternative for diagnosing PTB, especially when sputum collection is difficult. The combined testing approach enhances diagnostic yield and may improve early detection and treatment outcomes for PTB in resource-limited settings. Further studies are warranted to confirm these findings and explore the broader applicability of stool GeneXpert.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.